logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11142583 B1

PDFFull Text
Date of Patent:
Oct. 12, 2021

Filed:

May. 21, 2021

Bcma-car-natural killer (nk) cells and methods related thereto

Applicant:

Caribou Biosciences, Inc., Berkeley, CA (US);

Inventors:

Lijun Wu, Albany, CA (US);

Vita Golubovskaya, Richmond, CA (US);

Assignee:

Caribou Biosciences, Inc., Berkeley, CA (US);

Attorney:

Barbara G. McClung

Primary Examiner:

Zachary S Skelding

Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 9/0019 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); A61K 38/00 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising Vhaving the amino acid sequence of SEQ ID NO: 3 and Vhaving the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

Find Patent Forward Citations

Loading…